ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB The addition of CTC-DNA analysis to clinical trials could identify patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback